Home > Excluded studies: Update 3 - Drug Class...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

McDonagh M, Peterson K, Carson S, et al. Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet]. Portland (OR): Oregon Health & Science University; 2010 Jul.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Appendix EExcluded studies: Update 3

The following full-text publications were considered for inclusion but failed to meet the criteria for this report. See previous versions of the report on the Drug Effectiveness Review Project website for studies excluded previously.

2= outcome not included, 3=intervention not included, 4=population not included, 5=publication type not included, 6=study design not included.

Excluded trialsExclusion code
Head-to-head trials
Anonymous. A multicenter, randomized, double-blind, flexible-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using olanzapine positive control in subjects with an acute exacerbation of schizophrenia. http:​//wwwclinicaltrialsgov.2005.5
Anonymous. A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo using haloperidol positive control in subjects with an acute exacerbation of schizophrenia. http:​//wwwclinicaltrialsgov.2005.5
Anonymous. Long-term efficacy and safety evaluation of asenapine (10–20 mg/day) in subjects with schizophrenia or schizoaffective disorder, in a multicenter trial using olanzapine (10–20 mg/day) as a control. http:​//wwwclinicaltrialsgov.2005.5
Blonde L, Kan HJ, Gutterman EM, et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry. May 2008;69(5):741–748.6
Brecher M, Newcomer JW, Ratner RE, et al. Differential effects of quetiapine, olanzapine and risperidone on glucose metabolism: a 24-week study in schizophrenia. Schizophr Bull. 2007;33(2):423.5
Byerly MJ, Marcus RN, Tran Q-V, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. Feb 2009;107(2–3):218–222.6
Canuso C, Carothers J, Dirks B, Zhu Y, Schreiner A K-GC. A double-blind placebo-controlled trial comparing paliperidone er and quetiapine in patients with a recent acute exacerbation of schizophrenia. Schizophr Res. 2008;102(Suppl 2):252.5
Canuso CM, Grinspan A, Kalali A, al. e. Medication satisfaction in schizophrenia: A blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol. 2010a.2
Cazorla P, Panagides J, Alphs L, Kouassi A BR. Asenapine versus olanzapine in patients with predominant, persistent negative symptoms of schizophrenia. 161st Annual Meeting of the American Psychiatric Association. 2008.5
Cazorla P, Phiri P, den HW, et al. Long-term treatment with asenapine versus olanzapine in subjects with persistent negative symptoms of schizophrenia. Biological Psychiatry. 310p. 2009.5
Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews. 2009(3):CD006324.3
Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry. May 2009;70(5):717–729.6
Cuesta MJ, de Jalon EG, Campos M, Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry. 2009;194(5):439–445.2
Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)": Correction. The American journal of psychiatry. Jun 2009;166(6):731."5
Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). [erratum appears in Am J Psychiatry. 2009 Jun;166(6):731]. Am J Psychiatry. Jun 2009;166(6):675–682.2
Hanssens L, L'Italien G, Loze J-Y, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008;8:95.6
Huang C-L, Su K-P, Hsu H-B, Pariante CM. A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone. J Clin Psychiatry. 2007;68(5):803–805.2
Jeste DV, Jin H, Golshan S, et al. Discontinuation of quetiapine from an NIMH-funded trial due to serious adverse events. Am J Psychiatry. Aug 2009;166(8):937–938.5
Kahn RS. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial World Psychiatry. 2009;8(Suppl 1):44–45.5
Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. Feb 2010;167(2):181–189.3
Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. Jun 2007;64(6):633–647.2
Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. The American journal of psychiatry. Jul 2007;164(7):1061–1071.2
Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. European Psychiatry: the Journal of the Association of European Psychiatrists. Oct 2007;22(7):433–443.6
Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol. Dec 2008;28(6):601–607.2
Kolotkin RL, Corey-Lisle PK, Crosby RD, Kan HJ, McQuade RD. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. European Psychiatry: the Journal of the Association of European Psychiatrists. Dec 2008;23(8):561–566.6
Liu G CY. A comparison study on the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia. Mod Hosp. 2007;7(8):36–37.6
Liu-Seifert H, Osuntokun OO, Lin DY, Feldman PD. Predictors of persistence on treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia; 2010.5
Marder SR, Noordsy DL, Glynn SM, O'Keefe CD, Almeida MA, Drake Re BDR. Two year outcomes on risperidone and olanzapine in stable patients with schizophrenia. Schizophr Bull. 2007;33(2):444–445.5
Oriot P, Feys JL, Mertens de Wilmars S, et al. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab. Nov 2008;34(5):490–496.6
Pan G. A controlled study of aripiprazole and risperdal in the treatment of schizophrenia. Chinese Journal of Health Psychology [a[spacing cedilla]-a›1/2a [yen]a[masculine ordinal indicator][middle dot]a[inverted question mark][Latin small letter script f]c +a-[broken vertical bar]ae, a[inverted question mark]-]. 2007;15(4):363–364.5
Penn DL, Keefe RSE, Davis SM, et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res. Nov 2009;115(1):17–23.2
Perkins DO, Gu H, Weiden PJ, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. Jan 2008;69(1):106–113.6
Potkin SG, Cohen M, Baker RA, Jina AS, Nettler S AL. Asenapine, a novel psychotherapeutic agent with efficacy in positive and negative symptoms during acute episodes of schizophrenia: a randomized, placebo- and risperidone-controlled trial. Neuropsychopharmacology. 2005;30(Suppl 1):S112–113.5
Ravanic DB, Pantovic MM, Milovanovic DR, et al. Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia. Psychiatria Danubina. Jun 2009;21(2):179–186.2
Rosenheck RA, Leslie DL, Sindelar JL, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. Nov 2007;64(11):1259–1268.2
Rupnow MFT, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl SM. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo- controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin. Nov 2007;23(11):2815–2822.6
Sacchetti E, Galluzzo A, Valsecchi P, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. May 2009;110(1–3):80–89.5
Schering Plough. (Study A7501001) A double-blind, parallel, multicenter study to assess the effect of asenapine, quetiapine (ESroquel), and placebo on the QTc interval in patients with schizophrenia. 2004.2
Schreiner A, Rouillon F, Eriksson L, et al. Functional improvement in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry. 382p. 2009.5
Smeraldi E, Cavallaro R, Smalc VF, Bidzan L, Ceylan ME, Schreiner A LA. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Biological Psychiatry. 389p. 2009.5
Smith RC, Lindenmayer JP, Davis JM, Hu Q, Kelly E CJ. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Biological Psychiatry. 152p. 2009.5
Svestka J, Synek O, Tomanova J, Rodakova I, Cejpkova A. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuroendocrinology Letters. Dec 2007;28(6):881–888.2
Taylor D, Hanssens L, Loze J-Y, Pans M, L'Italien G, Marcus RN. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European Psychiatry: the Journal of the Association of European Psychiatrists. Aug 2008;23(5):336–343.6
Tschoner A, Engl J, Rettenbacher MA, et al. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study. J Clin Psychiatry. 2009;70(2):293–294.2
van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie. Jun 2008;53(6):400–405.2
Villari V, Rocca P, Fonzo V, Montemagni C, Pandullo P, Bogetto F. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. Feb 15 2008;32(2):405–413.4
Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol (Oxf). May 2009;23(3):305–314.6
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.
Cover of Drug Class Review: Atypical Antipsychotic Drugs
Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].
McDonagh M, Peterson K, Carson S, et al.
Portland (OR): Oregon Health & Science University; 2010 Jul.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...